Baszczuk Aleksandra, Thielemann Anna, Musialik Katarzyna, Kopczynski Jaroslaw, Bielawska Lena, Dzumak Anna, Kopczynski Zygmunt, Wysocka Ewa
Department of Laboratory Diagnostics, University of Medical Sciences.
Department of Internal Medicine, Metabolic Disorders and Hypertension, University of Medical Sciences.
J Nutr Sci Vitaminol (Tokyo). 2017;63(2):96-103. doi: 10.3177/jnsv.63.96.
The aim of the study was the assessment of the impact of supplementation with folic acid on the concentration of homocysteine, total cholesterol (TC), HDL- and LDL-cholesterol, triglycerides (TG), apoprotein AI (apoAI) and apoprotein B (apoB) in patients suffering from primary hypertension. The examined group comprised 42 patients suffering from primary hypertension. All examined patients underwent laboratory tests as follows: concentration of homocysteine, folic acid, TC, LDL-cholesterol, HDL-cholesterol, TG, apoAI and apoB. All patients were orally administered with 15 mg of folic acid per day for 45 d. After this period, all laboratory tests were repeated. Homocysteine concentration was measured by the FPIA method, concentrations of apoAI and apoB were measured by the nephelometric method, and other parameters with routine methods. After administration of 15 mg of folic acid to patients with primary hypertension, a considerable decrease in the concentration of homocysteine was observed in parallel with a substantive growth of HDL-cholesterol, as well as apoprotein AI concentrations and a reduction of the apoprotein B concentration. Results of statistical analysis indicated a significant correlation between the decline in homocysteine concentration and the increase in HDL-cholesterol concentration, as well as between the increase of folic acid concentration and the increase in apoAI concentration in patients following the intake of folic acid. The drop in homocysteine concentration through the supplementation with folic acid can cause quantitative changes in the lipid and lipoprotein parameters which, in consequence, may lead to the mitigation of risk concerning the development of atherosclerosis.
本研究的目的是评估补充叶酸对原发性高血压患者同型半胱氨酸、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）、载脂蛋白AI（apoAI）和载脂蛋白B（apoB）浓度的影响。研究组包括42例原发性高血压患者。所有受试患者均接受如下实验室检查：同型半胱氨酸、叶酸、TC、LDL-C、HDL-C、TG、apoAI和apoB的浓度。所有患者每天口服15 mg叶酸，共45天。在此期间过后，重复所有实验室检查。同型半胱氨酸浓度采用荧光偏振免疫分析（FPIA）法测定，apoAI和apoB的浓度采用散射比浊法测定，其他参数采用常规方法测定。对原发性高血压患者给予15 mg叶酸后，观察到同型半胱氨酸浓度显著下降，同时HDL-C浓度、载脂蛋白AI浓度大幅升高，载脂蛋白B浓度降低。统计分析结果表明，在摄入叶酸后，患者同型半胱氨酸浓度下降与HDL-C浓度升高之间、叶酸浓度升高与apoAI浓度升高之间存在显著相关性。通过补充叶酸降低同型半胱氨酸浓度可引起脂质和脂蛋白参数的定量变化，进而可能减轻动脉粥样硬化发展的风险。
